Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio di mezagitamab negli adulti con nefropatia IGA primaria Condizioni renali

3 novembre 2026 aggiornato da: Takeda

Un studio multicentrico di fase 3, randomizzato, in doppio cieco, controllato con placebo per valutare l'efficacia e la sicurezza di Mezagitamab (TAK-079) nei partecipanti allo studio con nefropatia IGA primaria in combinazione con terapia di fondo stabile

Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo.

Participants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed by chance in either the mezagitamab or placebo treatment group at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. Participants can be in the study for 2 years (104 weeks). Participants will receive study treatment for about half a year (22 weeks) and then be observed for the remainder of the study (about 1.5 years). During observation, participants will continue to have check-ups about every month.

In the open-label group, a small number of participants who either have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab.

During the study, participants will visit their study clinic several times.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

347

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Ciudad Autonoma Buenos Aires, Argentina, 1280
        • Reclutamento
        • Hospital Britanico de Buenos Aires
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Hernan Trimarchi Jurado
      • Córdoba, Argentina, X5016
        • Reclutamento
        • Clinica Privada Velez Sarsfield
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Rafael Alberto Maldonado
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1425AGC
        • Reclutamento
        • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Alejandra Smuclir Quevedo
    • La Plata
      • Buenos Aires, La Plata, Argentina, 1902
        • Reclutamento
        • Framingham Centro Medico
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Martin Mamberti
    • New South Wales
      • Liverpool, New South Wales, Australia
        • Reclutamento
        • South Western Sydney Local Health District - University of New South Wales - Liverpool Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Beata Zahorowska
    • Queensland
      • Milton, Queensland, Australia
        • Reclutamento
        • Core Research Group
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • David Colquhoun
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Reclutamento
        • Eastern Health
        • Investigatore principale:
          • Darren Lee
        • Contatto:
          • Site Contact
      • Clayton, Victoria, Australia
        • Reclutamento
        • Monash Heath - Monash University - Monash Medical Centre
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Jessica Ryan
      • St Albans, Victoria, Australia, 3021
        • Reclutamento
        • Western Health Sunshine Hospital
        • Investigatore principale:
          • Eugenia Pedagogos
        • Contatto:
          • Site Contact
      • Linz, Austria, 4040
        • Reclutamento
        • Johannes Kepler Universitat Linz, Universitatsklinik fur Innere 2
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Alexander Moschen
      • Vienna, Austria, 1090
        • Reclutamento
        • Medizinische Universitat Wien (Medical University of Vienna - Austria)
        • Investigatore principale:
          • Rainer Oberbauer
        • Contatto:
          • Site Contact
    • Alberta
      • Calgary, Alberta, Canada, T2R 0X7
        • Reclutamento
        • Sheldon M. Chumir Health Centre
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Louis Girard
    • Ontario
      • London, Ontario, Canada, N6A5A5
        • Reclutamento
        • London Health Sciences Centre
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Matthew Weir
      • Toronto, Ontario, Canada, M4G 3E8
        • Reclutamento
        • Sunnybrook Health Sciences Centre
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Michelle Hladunewich
      • Olomouc, Cechia, 779 00
        • Reclutamento
        • Fakultni nemocnice Olomouc
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Karel Krejci
      • Prague, Cechia
        • Reclutamento
        • First Faculty of Medicine Charles University
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Vladimir Tesar
    • Moravskoslezsk Kraj
      • Nový Jičín, Moravskoslezsk Kraj, Cechia, 741 01
        • Reclutamento
        • Nemocnice AGEL Novy Jicin a.s
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Vaclava Honova
    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100034
        • Reclutamento
        • Peking University First Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Jicheng Lv
      • Changping, Beijing Municipality, Cina, 102218
        • Reclutamento
        • Beijing Tsinghua Changgung Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Yuehong Li
    • Fujian
      • Xiamen, Fujian, Cina, 361004
        • Reclutamento
        • Zhongshan Hospital Xiamen University
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Bo Xu
    • Guangdong
      • Guangdong, Guangdong, Cina, Guangdong
        • Reclutamento
        • The First Affiliated Hospital of Sun Yat-sen University
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Wei Chen
      • Guangzhou, Guangdong, Cina, 510080
        • Reclutamento
        • Guangdong General Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Zhiming Ye
      • Shenzhen, Guangdong, Cina, 518000
        • Reclutamento
        • Peking University Shenzhen Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Zu-Ying Xiong
    • Hunan
      • Changsha, Hunan, Cina, 410013
        • Reclutamento
        • The Third Xiangya Hospital of Central South University Yuelu District
        • Investigatore principale:
          • Hao Zhang
        • Contatto:
          • Site Contact
    • Inner Mongolia
      • Baotou, Inner Mongolia, Cina, 14010
        • Reclutamento
        • The First Affiliated Hospital of Baotou Medical College
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Zengyan Li
    • Jiangsu
      • Nanjing, Jiangsu, Cina, 210009
        • Reclutamento
        • Zhongda Hospital Southeast University
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Liu Bicheng
      • Nantong, Jiangsu, Cina, 226001
        • Reclutamento
        • Affiliated Hospital of Nantong University
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Xinzhong Huang
      • Wuxi, Jiangsu, Cina, 214023
        • Reclutamento
        • Wuxi People's Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Liang Wang
    • Jiangxi
      • Nanchang, Jiangxi, Cina, 330006
        • Reclutamento
        • The First Affiliated Hospital of Nanchang University
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Yan Yan
    • Shandong
      • Jinan, Shandong, Cina, 250012
        • Reclutamento
        • Shandong University - Qilu Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Xiang-Dong Yang
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200000
        • Reclutamento
        • Shanghai Jiao Tong University School of Medicine (SJTUSM) - Renji Hospital - Eastern Branch
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Leyi Gu
      • Shanghai, Shanghai Municipality, Cina, 200025
        • Reclutamento
        • Ruijin Hospital of Shanghai Jiaotong University School of Medicine
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Jingyuan Xie
    • Sichuan
      • Chengdu, Sichuan, Cina, 610000
        • Reclutamento
        • West China Hospital Sichuan University
        • Investigatore principale:
          • Ping Fu
        • Contatto:
          • Site Contact
      • Chengdu, Sichuan, Cina, 610072
        • Reclutamento
        • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Guisen Li
      • Yibin, Sichuan, Cina, 644099
        • Reclutamento
        • The Second People's Hospital of Yibin
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Deqiong Xie
    • Xiangzhou District, Guangdong Province
      • Zhuhai, Xiangzhou District, Guangdong Province, Cina, 519000
        • Reclutamento
        • Fifth Affiliated Hospital Sun Yat-Sen University
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Cheng Wang
    • Zhejiang
      • Hangzhou, Zhejiang, Cina
        • Reclutamento
        • The Second Affiliated Hospital, Zhejiang University, School of Medicine
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Kunling Ma
      • Ningbo, Zhejiang, Cina, 315010
        • Reclutamento
        • The First Affiliated Hospital of Ningbo University
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Xueyan Bian
      • Seoul, Corea del Sud, 3722
        • Reclutamento
        • Severance Hospital, Yonsei University Health System
        • Investigatore principale:
          • Seung Hyeok Han
        • Contatto:
          • Site Contact
      • Seoul, Corea del Sud, 3080
        • Reclutamento
        • Seoul National University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Dong Ki Kim
      • Seoul, Corea del Sud, 7061
        • Reclutamento
        • Seoul National University Boramae Medical Center
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Jung Pyo Lee
    • Gyeonggi-do
      • Yongin-si, Gyeonggi-do, Corea del Sud, 16995
        • Reclutamento
        • Yongin Severance Hospital, Yonsei University Health System
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Young Su Joo
    • Gyeonggido
      • Suwon, Gyeonggido, Corea del Sud, 16499
        • Reclutamento
        • Ajou University Hospital-Primary Research Location
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Inwhee Park
    • Seongnam
      • Seongnam-si, Seongnam, Corea del Sud, 13620
        • Reclutamento
        • Seoul National University Bundang Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Ho-Jun Chin
      • Bordeaux, Francia, 33076
        • Reclutamento
        • CHU Bordeaux, CHU Pellegrin
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Claire Rigothier
      • Limoges, Francia, 87042
        • Reclutamento
        • CHU Limoges Service de Nephrology
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Fatouma Toure
      • Montpellier, Francia, 34090
        • Reclutamento
        • Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Lapeyronie
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Moglie Le Quintrec
      • Nantes, Francia, 44093
        • Reclutamento
        • CHU de Nantes
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Simon Ville
      • Paris, Francia, 75020
        • Reclutamento
        • Hospital Tenon
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Khalil Karoui
    • Paris
      • Créteil, Paris, Francia, 94000
        • Reclutamento
        • Hospital Henri Mondor
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Vincent Audard
      • Mainz, Germania, 55131
        • Reclutamento
        • Universitaetsmedizin der Johannes - Gutenberg Universitaet Mainz
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Julia Weinmann-Manke
    • North Rhine-Westphalia
      • Aachen, North Rhine-Westphalia, Germania, 52074
        • Reclutamento
        • Uniklinik RWTH Aachen
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Claudia Seikrit
    • Thuringia
      • Jena, Thuringia, Germania, 7747
        • Reclutamento
        • Universitaetsklinikum Jena
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Martin Busch
    • Aichi-ken
      • Kasugai-Shi, Aichi-ken, Giappone, 486-8510
        • Reclutamento
        • Kasugai Municipal Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Yosuke Saka
      • Nagoya, Aichi-ken, Giappone, 466-8650
        • Reclutamento
        • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Shoji Saito
      • Toyoake-shi, Aichi-ken, Giappone, 470-1192
        • Reclutamento
        • Fujita Health University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Naotake Tsuboi
    • Chiba
      • Chiba, Chiba, Giappone, 260-8712
        • Reclutamento
        • National Hospital Organization Chiba Medical Center Chibahigashi National Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Takehiko Kawaguchi
    • Fukuoka
      • Fukuoka, Fukuoka, Giappone, 812-8582
        • Reclutamento
        • Kyushu University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Toshiaki Nakano
    • Fukushima
      • Fukushima, Fukushima, Giappone, 960-1295
        • Reclutamento
        • Fukushima Medical University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Kazama Junichiro
    • Hiroshima
      • Hiroshima, Hiroshima, Giappone, 734-8551
        • Reclutamento
        • Hiroshima University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Takao Masaki
    • Hokkaido
      • Sapporo, Hokkaido, Giappone, 060-8648
        • Reclutamento
        • Hokkaido University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Daigo Nakazawa
    • Kanagawa
      • Kamakura-shi, Kanagawa, Giappone, 247-8533
        • Reclutamento
        • Shonan Kamakura General Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Hidaka Sumi
      • Kawasaki-shi, Kanagawa, Giappone, 213-8587
        • Reclutamento
        • Toranomon Hospital Kajigaya
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Naoki Sawa
      • Yokohama, Kanagawa, Giappone, 236-0004
        • Reclutamento
        • Yokohama City University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Kouichi Tamura
    • Miyagi
      • Sendai, Miyagi, Giappone, 981-3281
        • Reclutamento
        • Japan Community Health care Organization Sendai Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Santoru Sanada
    • Nara
      • Kashihara-shi, Nara, Giappone, 634-8522
        • Reclutamento
        • Nara Medical University Hospital
        • Investigatore principale:
          • Kazuhiko Tsuruya
        • Contatto:
          • Site Contact
      • Nara, Nara, Giappone, 630-8581
        • Reclutamento
        • Nara Prefecture General Medical Center
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Hideo Tsushima
    • Oita Prefecture
      • Yufu-shi, Oita Prefecture, Giappone, 879-5593
        • Reclutamento
        • Oita University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Fukuda Akihiro
    • Osaka
      • Osaka, Osaka, Giappone, 530-8480
        • Reclutamento
        • Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofuka
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Takeshi Matsubara
    • Saitama
      • Koshigaya-shi, Saitama, Giappone, 343-8555
        • Reclutamento
        • Dokkyo Medical University Saitama Medical Center
        • Investigatore principale:
          • Tetsuro Takeda
        • Contatto:
          • Site Contact
    • Tokyo
      • Bunkyo-ku, Tokyo, Giappone, 113-8431
        • Reclutamento
        • Juntendo University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Yusuke Suzuki
      • Shinjuku-Ku, Tokyo, Giappone, 160-0023
        • Reclutamento
        • Tokyo Medical University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Takahito Moriyama
    • Yamanashi
      • Chuo-shi, Yamanashi, Giappone, 409-3898
        • Reclutamento
        • University of Yamanashi Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Ayumu Nakashima
    • Hong Kong Island
      • Hong Kong, Hong Kong Island, Hong Kong
        • Reclutamento
        • The University of Hong Kong - Department of Medicine
        • Investigatore principale:
          • Sydney Chi Wai Tang
        • Contatto:
          • Site Contact
      • Bologna, Italia, 40138
        • Reclutamento
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Gaetano La Manna
      • Brescia, Italia, 25124
        • Reclutamento
        • ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Federica Mescia
      • Genoa, Italia, 16132
        • Reclutamento
        • IRCCS Ospedale Policlinico San Martino
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Francesca Viazzi
      • Messina, Italia, 98122
        • Reclutamento
        • Az Ospedaliera Universitaria Policlinico G Martino
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Domenico Santoro
      • Milan, Italia, 20100
        • Reclutamento
        • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Giuseppe Castellano
      • Pavia, Italia, 27100
        • Reclutamento
        • Istituto Maugeri IRCCS Pavia
        • Investigatore principale:
          • Ciro Esposito
        • Contatto:
          • Site Contact
      • Piacenza, Italia, 29121
        • Reclutamento
        • Azienda Unita Sanitaria Locale Piacenza (AUSL) Ospedale "Guglielmo da Saliceto
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Roberto Scarpioni
      • Torino, Italia, 10126
        • Reclutamento
        • AOU Citta della Salute e della Scienza di Torino
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Luigi Biancone
      • Kuala Lumpur, Malaysia, 50603
        • Reclutamento
        • Universiti Malaya Medical Centre (UMMC)
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Soo Kun Lim
    • Kuala Lumpur
      • Kuala Lumpur, Kuala Lumpur, Malaysia, 56000
        • Reclutamento
        • Universiti Kebangsaan Malaysia (UKM) - Medical Centre (Pusat Perubatan) (Hospital Canselor Tuanku Muhriz (HCTM))
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Lydia Kamaruzaman
    • Pahang
      • Kuantan, Pahang, Malaysia, 25100
        • Reclutamento
        • Hospital Tengku Ampuan Afzan
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Fariz Safhan Mohamad Nor
    • Perak
      • Taiping, Perak, Malaysia, 34000
        • Reclutamento
        • Hospital Taiping
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Kok Seng Teng
    • Selangor
      • Kajang, Selangor, Malaysia, 43000
        • Reclutamento
        • Hospital Sultan Idris Shah Serdang (Hospital Serdang)
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Li Lian Tay
      • Subang Jaya, Selangor, Malaysia, 47500
        • Reclutamento
        • Sunway Medical Centre (SMC)
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Rosnawati Yahya
      • Bergen, Norvegia, 5021
        • Reclutamento
        • Haukeland Universitetssjukehus
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Thomas Knoop
      • Grålum, Norvegia, 1714
        • Reclutamento
        • Sykehuset Ostfold
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Dumitrescu Ioana-Elena
      • Stavanger, Norvegia
        • Reclutamento
        • Stavanger Universitetssjukehus - Helse Stavanger HF
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Goransson Lasse
      • Trondheim, Norvegia, 7030
        • Reclutamento
        • Universitetssykehuset I Trondheim - St. Olavs Hospital - Nevroklinikken
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Yngvar Haaskjold
    • Akershus
      • Lorenskog, Akershus, Norvegia, 1478
        • Reclutamento
        • Akershus University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Bartlomiej Witczak
    • Vestfold
      • Tønsberg, Vestfold, Norvegia
        • Reclutamento
        • Sykehuset I Vestfold
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Kjellevold Stig Arne
      • Leiden, Olanda, 2333 ZA
        • Reclutamento
        • Leids Universitair Medisch Center
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Joris Rotmans
      • Nieuwegein, Olanda, 3435CM
        • Reclutamento
        • Sint Antonius ziekenhuis Utrecht/Nieuwegein
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Gurbey Ocak
      • Nijmegen, Olanda, 6525 GA
        • Reclutamento
        • Radboud Universitair Medisch Centrum
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Raphael Duivenvoorden
      • Utrecht, Olanda, 3584 CX
        • Reclutamento
        • UMC Utrecht
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Sabine Meijvis
    • North Holland
      • Amsterdam, North Holland, Olanda, 1105 AZ
        • Reclutamento
        • Amsterdam UMC - Locatie AMC (Academisch Medisch Centrum)
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Marc Hilhorst
      • Gmina Świecie, Polonia, 86-100
        • Reclutamento
        • Nowy Szpital Sp Zo.o
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Andrzej Brymora
      • Krakow, Polonia, 31-559
        • Reclutamento
        • SCM Sp. z o.o.
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Dariusz Aksamit
      • Lodz, Polonia
        • Reclutamento
        • Indywidualna Specjalistyczna Praktyka Lekarska
        • Investigatore principale:
          • Michal Nowicki
        • Contatto:
          • Site Contact
      • Wroclaw, Polonia, 50-981
        • Reclutamento
        • 4th Military Clinical hospital /Polyclinic SP ZOZ
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Magdalena Krajewska
      • Canterbury, Regno Unito, CT1 3PA
        • Reclutamento
        • Kent & Canterbury Hospital, Canterbury
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Tharindra Somasinghe
      • Hull, Regno Unito
        • Reclutamento
        • Hull University Teaching Hospitals NHS Trust
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Sunil Bhandari
      • Leicester, Regno Unito
        • Reclutamento
        • Leicester General Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Chee Kay Cheung
      • London, Regno Unito, WC2R 2LS
        • Reclutamento
        • King's College Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Sapna Shah
      • London, Regno Unito, SW17 0QT
        • Reclutamento
        • St George's University Hospitals NHS Foundation Trust
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Richard Hull
      • Nottingham, Regno Unito
        • Reclutamento
        • Nottingham University Hospitals NHS Trust - City Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Matthew Hall
      • Preston, Regno Unito, PR29HT
        • Reclutamento
        • Lancashire Teaching Hospital NHS Foundation Trust
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Arvind Ponnusamy
      • Sheffield, Regno Unito
        • Reclutamento
        • Northern General Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Arif Khwaja
    • Greater London
      • London, Greater London, Regno Unito, SE1 9RT
        • Reclutamento
        • Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Dimitrios-Anestis Moutzouris
    • United Kingdom of Great Britain and Northern Ireland
      • Birmingham, United Kingdom of Great Britain and Northern Ireland, Regno Unito
        • Reclutamento
        • Birmingham Heartlands Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Bamidele Tokunbo Ajayi
      • Singapore, Singapore
        • Reclutamento
        • National University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Boon Wee Teo
      • Singapore, Singapore, 169608
        • Reclutamento
        • Singapore General Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Jason Choo
      • Singapore, Singapore, 308433
        • Reclutamento
        • Tan Tock Seng Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • See Cheng Yeo
      • Ljubljana, Slovenia, 1000
        • Reclutamento
        • University Medical Centre Ljubljana
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Andreja Ales Rigler
      • Maribor, Slovenia
        • Reclutamento
        • University Clinical Centre Maribor
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Sebastjan Bevc
      • Barcelona, Spagna, 8035
        • Reclutamento
        • Hospital Universitari Vall d'Hebron
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Irene Agraz Pamplona
      • Barcelona, Spagna, 8003
        • Reclutamento
        • Hospital del Mar
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Eva Rodriguez Garcia
      • Madrid, Spagna, 28027
        • Reclutamento
        • Universidad de Navarra - Clinica Universidad de Navarra
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Jose Maria Mora Gutierrez
      • Madrid, Spagna, 28040
        • Reclutamento
        • Fundacion Jimenez Diaz
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Roberto Scarpioni
      • Seville, Spagna, 41013
        • Reclutamento
        • Hospital Universitario Virgen del Rocio - PPDS
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Manuel Lopez Mendoza
    • Barcelona
      • Badalona, Barcelona, Spagna, 8915
        • Reclutamento
        • Hospital Universitari Germans Trias i Pujol
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Iara Karlla Da Silva Santos
    • Bizkaia
      • Barakaldo, Bizkaia, Spagna, 48903
        • Reclutamento
        • Hospital Universitario de Cruces
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Laura Bueno Lopez
    • Navarre
      • Pamplona, Navarre, Spagna, 31008
        • Reclutamento
        • Universidad de Navarra - Clinica Universidad de Navarra
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Jose Maria Mora Gutierrez
    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35233-2110
        • Reclutamento
        • UAB Nephrology Research Clinic at Paula Building
        • Investigatore principale:
          • Dana Rizk
        • Contatto:
          • Site Contact
      • Montgomery, Alabama, Stati Uniti, 36117
        • Reclutamento
        • DCR Montgomery
        • Investigatore principale:
          • Vinayak Ramanath
        • Contatto:
          • Site Contact
    • Arizona
      • Surprise, Arizona, Stati Uniti, 85374
        • Reclutamento
        • Panoramic Health - Southwest Kidney Institute, PLC
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Minesh Rajpal
    • California
      • Fremont, California, Stati Uniti, 94538
        • Reclutamento
        • Panoramic Health - West Coast Kidney Institute (Fremont)
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Varun Chawla
      • Los Angeles, California, Stati Uniti, 90022
        • Reclutamento
        • Academic Medical Research Institute
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Mohammed El-Shahwy
      • Los Angeles, California, Stati Uniti, 90095
        • Reclutamento
        • UCLA University of California Los Angeles
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Anjay Rastogi
      • Orange, California, Stati Uniti, 92868-3201
        • Reclutamento
        • University of California Irvine
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Ramy Hanna
      • San Francisco, California, Stati Uniti, 94118
        • Reclutamento
        • Kaiser Permanente San Francisco Medical Center
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Ali Poyan-Mehr
    • Florida
      • Jacksonville, Florida, Stati Uniti, 32250
        • Reclutamento
        • Panoramic Health - Florida Kidney Physicians, LLC (Jacksonville)
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Prasanth Krish
      • Lauderdale Lakes, Florida, Stati Uniti, 33313-1607
        • Reclutamento
        • South Florida Research Institute
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Edouard Martin
      • Melbourne, Florida, Stati Uniti, 32901
        • Reclutamento
        • Panoramic Health - Florida Kidney Physicians, LLC (Melbourne)
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Claus Peter Spies
      • Miami, Florida, Stati Uniti, 33127
        • Reclutamento
        • Bioresearch Partners
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Jose Miguel Cardona-Guzman
      • Miami, Florida, Stati Uniti, 33176
        • Reclutamento
        • Total Health and Research Center (THRC)
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Jeffrey Maldonado
      • Orlando, Florida, Stati Uniti, 32806
        • Reclutamento
        • CTR Oakwater, LLC
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Arvind Madan
      • Pembroke Pines, Florida, Stati Uniti, 33029
        • Reclutamento
        • Bioresearch Partners
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Max Benjamin
      • Riverview, Florida, Stati Uniti, 33578
        • Reclutamento
        • Panoramic Health - Florida Kidney Physicians, LLC (Tampa)
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Amit Augustine Johnsingh
      • Sanford, Florida, Stati Uniti, 32771
        • Reclutamento
        • Infigo Clinical Research LLC
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Sayed Husain
    • Georgia
      • Columbus, Georgia, Stati Uniti, 31904
        • Reclutamento
        • DCR Columbus
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Tamorie Smith
      • East Point, Georgia, Stati Uniti, 30344
        • Reclutamento
        • Panoramic Health - Southeast Kidney Associates
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Charmaine Ifeoma Emelife
    • Idaho
      • Boise, Idaho, Stati Uniti, 83706
        • Reclutamento
        • CARE Institute - Boise Kidney
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Arnold Silva
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Reclutamento
        • Northwestern University
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Yonatan Peleg
      • Rockford, Illinois, Stati Uniti, 61107
        • Reclutamento
        • Panoramic Health - RNA of Rockford, LLC dba Rockford Nephrology Associates
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Syed Mustafa Ahmed
    • Louisiana
      • Shreveport, Louisiana, Stati Uniti, 71101
        • Reclutamento
        • Northwest Louisiana Nephrology
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Marwan Kaskas
    • Michigan
      • Lansing, Michigan, Stati Uniti, 48911
        • Reclutamento
        • Ingham Nephrology & Hypertension, P.C.
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Brian Cousino
      • Pontiac, Michigan, Stati Uniti, 48341
        • Reclutamento
        • Elixia MKC
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Fahd Al-Saghir
      • Saint Joseph, Michigan, Stati Uniti, 49085
        • Reclutamento
        • Panoramic Health - Lake Michigan Nephrology, PLC
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Oliver Chambers Songlingco
    • Minnesota
      • Edina, Minnesota, Stati Uniti, 55435
        • Reclutamento
        • DCR Edina
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Shannon Doyle
    • Missouri
      • City of Saint Peters, Missouri, Stati Uniti, 63376
        • Reclutamento
        • Elixia MNA
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Gary Singer
      • Kansas City, Missouri, Stati Uniti, 64111
        • Reclutamento
        • Clinical Research Consultants a JCCT Company
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Ahmed Awad
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87109
        • Reclutamento
        • Renal Medicine Associates - Frenova F1
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Jayant Kumar
    • North Carolina
      • Winston-Salem, North Carolina, Stati Uniti, 27103
        • Reclutamento
        • Brookview Hills Research Associates, LLC
        • Investigatore principale:
          • Nicholas McLean
        • Contatto:
          • Site Contact
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45212
        • Reclutamento
        • Panoramic Health - Kidney and Hypertension Center
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • James Davis
    • Pennsylvania
      • Media, Pennsylvania, Stati Uniti, 19063
        • Reclutamento
        • Panoramic Health - Clinical Renal Associates, Ltd.
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Nathan Okechukwu
      • Philadelphia, Pennsylvania, Stati Uniti, 19107
        • Reclutamento
        • Thomas Jefferson University
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Charlene Deng
    • Rhode Island
      • East Providence, Rhode Island, Stati Uniti, 02914
        • Reclutamento
        • Panoramic Health - Nephrology Associates, Inc.
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Larissa Kruger Gomes
    • Texas
      • Dallas, Texas, Stati Uniti, 75230
        • Reclutamento
        • Dallas Renal Group
        • Investigatore principale:
          • Irfan Agha
        • Contatto:
          • Site Contact
      • El Paso, Texas, Stati Uniti, 79902
        • Reclutamento
        • DCR - El Paso
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Simon Rodriguez
      • Houston, Texas, Stati Uniti, 77054
        • Reclutamento
        • Provecta Research Network
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Sreedhar Mandayam
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • Houston Methodist Research Institute - Department of Medicine
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Peter Nguyen
      • Katy, Texas, Stati Uniti, 77450
        • Reclutamento
        • Nephrology Associates of Houston PLLC
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Syed Hussain
      • San Antonio, Texas, Stati Uniti, 78215
        • Reclutamento
        • Sun Research Institute
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Reyes Leonel
      • San Antonio, Texas, Stati Uniti, 78251
        • Reclutamento
        • DCR San Antonio
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Tahira Alves
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84115
        • Reclutamento
        • Utah Kidney Research Institute
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Sanjiv Anand
    • Virginia
      • Arlington, Virginia, Stati Uniti, 22205
        • Reclutamento
        • Panoramic Health - Virginia Nephrology Group
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Renuka Sothinathan
    • West Virginia
      • Morgantown, West Virginia, Stati Uniti, 26506
        • Reclutamento
        • West Virginia University
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Bethany Pellegrino
      • Linköping, Svezia
        • Reclutamento
        • Renal Medicine Linkoping University/ Linkoping University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Annette Bruchfeld
      • Zurich, Svizzera, 8091
        • Reclutamento
        • University Hospital Zurich
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Britta George
      • Kaohsiung City, Taiwan, 807
        • Reclutamento
        • Kaohsiung Medical University - Chung-Ho Memorial Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Yi Wen Chiu
      • New Taipei City, Taiwan
        • Reclutamento
        • Taipei Medical University Shuang Ho Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Mai-Szu Wu
      • Taichung, Taiwan, 40705
        • Reclutamento
        • Taichung Veterans General Hospital
        • Investigatore principale:
          • Ming-Ju Wu
        • Contatto:
          • Site Contact
      • Taichung, Taiwan
        • Reclutamento
        • China Medical University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Ping-Chin Lai
      • Zhongzheng, Taiwan, 100
        • Reclutamento
        • National Taiwan University Hospital
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Jenq-Wen Huang
      • Kocaeli, Turchia (Türkiye)
        • Reclutamento
        • Kocaeli Universitesi Tip Fakultesi Arastirma ve Uygulama Hastanesi
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Necmi Eren
    • Battalgazi
      • Malatya, Battalgazi, Turchia (Türkiye), 44280
        • Reclutamento
        • Turgut Ozal Medical Center
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Ozkan Ulutas
    • Gaziantep
      • Şahinbey, Gaziantep, Turchia (Türkiye), 27310
        • Reclutamento
        • Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Fatih Mehmet Erdur
    • Istanbul
      • Fatih, Istanbul, Turchia (Türkiye), 34098
        • Reclutamento
        • Istanbul Universitesi Cerrahpasa Tip Fakultesi
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Nurhan Seyahi
    • Melikgazi
      • Kayseri, Melikgazi, Turchia (Türkiye), 38039
        • Reclutamento
        • Erciyes University
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Bulent Tokgoz
    • Onikisubat
      • Kahramanmaraş, Onikisubat, Turchia (Türkiye), 46040
        • Reclutamento
        • Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Avsar Mah
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Orcum Altunoren
    • Selcuklu
      • Konya, Selcuklu, Turchia (Türkiye), 42280
        • Reclutamento
        • Necmettin Erbakan University
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Kultigin Turkmen
      • Budapest, Ungheria, 1083
        • Reclutamento
        • Semmelweis Egyetem - Belgyogyaszati es Onkologiai Klinika (I.sz. Belgyogyaszati Klinika)
        • Contatto:
          • Site Contact
        • Investigatore principale:
          • Akos Petho

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

  • Inclusion Criteria:

To be eligible to participate in this trial, participants must meet all the following criteria:

  1. Either UPCR greater than or equal to (≥) 0.8 gram per gram (g/g) or urine protein excretion (UPE) ≥1 grams per day (g/day), calculated from at least one 24-hour urine collection during the screening period (or pre-screening, if applicable) (only applicable for the main trial).

  2. eGFR greater than (>)30 milliliters per minute per 1.73 meter square (mL/min/1.73m^2) at screening based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (only applicable for the main trial).

  3. No prior exposure to anti- cluster of differentiation 38 (CD38) therapy period (except for open-label cohort participants meeting Inclusion Criterion No. 10.a).

  4. The participant is aged ≥ 18 years or the local legal age as applicable.

  5. The participant (and the participant's legally acceptable representative, as applicable per local regulations or determination) has provided informed consent (that is, in writing, documented via a signed and dated informed consent form [ICF]) and any required privacy authorization before the initiation of any clinical trial procedures.

  6. Diagnosis of primary immunoglobulin A nephropathy (IgAN) supported by a renal biopsy report that is dated more recently than 10 years before the signing of the informed consent for the clinical trial. The redacted report must be made available for review. A renal biopsy must be performed during screening for participants without a biopsy report within 10 years.

  7. Participants must be on stable renin-angiotensin-aldosterone system (RAAS) inhibitor therapy with an angiotensin-converting enzyme inhibitor (ACE-I) and/or angiotensin receptor blocker (ARB) or endothelin receptor antagonist (ERA) or mineralocorticoid receptor antagonist (MRA) agent for at least 12 weeks before signing the ICF with dosing at the maximally tolerated or labeled dose as determined by the investigator, with the intent to continue stable dosing during the clinical trial. Those intolerant of RAAS inhibitor therapy are potentially eligible after consultation with the medical monitor. Intolerance is defined as a documented side effect causing discontinuation of the therapy.

  8. Resting blood pressure less than or equal to (≤)150 millimeters of mercury (mmHg) systolic and ≤100 mmHg diastolic.

  9. Female participants of childbearing potential who are not pregnant during screening (confirmed by negative serum human chorionic gonadotropin [hCG]) and on Visit 1 before first dose of trial intervention (confirmed by negative urine pregnancy test).

  10. Any one of the following (only applicable for participants in the open-label cohort):

    1. Participants in Trial TAK-079-1006 who completed the Week 96 visit or the retreatment period with either UPCR >0.5 g/g or UPE >0.5 g/d calculated from a 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR >30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.

    2. UPCR <0.8 g/g and UPE ≥0.75 and <1.0 g/day, by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR > 30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.

    3. UPCR ≥ 0.8 g/g or UPE ≥ 1.0 g/d by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR ≥25 and ≤30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.

      • Exclusion Criteria:

A participant who meets any of the following criteria will be excluded from participation in this trial:

  1. Kidney biopsy exhibiting significant concomitant renal disease other than IgAN (for example, diabetic nephropathy, lupus nephritis, minimal change disease).

  2. Secondary IgAN (such as with significant liver disease, inflammatory bowel disease, and seronegative spondyloarthropathies), and immunoglobulin A (IgA) vasculitis.

  3. Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months before the signing of the ICF).

  4. Diagnosis of nephrotic syndrome defined as 24-hour proteinuria >3.5 g/day and hypoalbuminemia (<3.0 grams per deciliter [g/dL]) with or without peripheral edema.

  5. Renal or other organ transplantation prior to or expected during the clinical trial.

  6. Treatment with oral immunosuppressive agents (including cyclophosphamide, mycophenolate mofetil, cyclosporine, azathioprine, calcineurin inhibitors) or biologic therapy for immunomodulation (including immunomodulatory monoclonal or polyclonal antibodies) within 6 months (both B-cell and non-B-cell directed agents) before signing of the ICF.

  7. If the participant has received anti-CD20 treatment, the participant is excluded if either of the following apply:

    1. The last dose was received within 6 months before the signing of the ICF.
    2. The last dose was received between 6 and 12 months before the signing of the ICF and the participant has a CD19+ count below the lower limit of normal.

    Note: Participants who have received the last dose of anti-CD20 treatment >12 months before the signing of the ICF are not excluded from clinical trial participation based on this criterion and are not required to undergo CD19+ testing.

  8. Within 4 months of the screening visit, use of either a) systemic corticosteroids at an average dose of 40 milligrams (mg) prednisone equivalent or higher for more than 14 days or b) oral budesonide delayed release capsules.

  9. The participant has received a live or live-attenuated vaccine within 4 weeks before signing the ICF or has any live or live-attenuated vaccine planned during the clinical trial.

  10. Participation in any other investigational drug trial (including vaccine trial) with receipt of at least 1 dose of investigational drug, or has been exposed to another investigational agent within 4 weeks or 5 half-lives, whichever is longer, before Visit 1.

  11. The participant has active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).

  12. The participant has had any of the following types of infections within the specified timeframes where applicable:

    1. Active bacterial, viral, or fungal infection (except for the common cold and onychomycosis), or any other serious infection within 2 weeks of signing the ICF. Any anti-infective course for infection must be completed at least 2 weeks before Visit 1.
    2. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) infection within 4 weeks of signing the ICF.
    3. Opportunistic infection or treatment for an opportunistic infection less than or equal to (≤)12 weeks before signing the ICF.
    4. Active tuberculosis (TB), any history of prior active TB, or any signs or symptoms of active TB infection (including but not limited to chronic fever, chronic productive cough, night sweats, weight loss, or malnutrition) as judged by the investigator.
    5. For participants in European Union (EU) member states, positive or 2 indeterminant QuantiFERON results, unless there is documentation of prior complete treatment for latent TB, or participant has initiated prophylaxis based on local guidelines and in consultation with a pulmonology or infectious disease specialist prior to the first administration of IMP.
  13. In the opinion of the investigator, the participant is currently experiencing any medical condition that might interfere with participation in the trial (for example, significant ocular, cardiovascular, pulmonary, hematologic, gastrointestinal, endocrinologic, hepatic, renal, neurologic, malignancy, infectious disease, immunodeficiency, or alcohol and drug abuse), that poses an added risk for the participant or could confound the assessment of trial results.

  14. In the opinion of the investigator, the participant has a serious medical or psychiatric illness that could potentially interfere with the completion of treatment.

  15. The participant has a history of major surgery within 3 months before screening (or longer, at the discretion of the investigator); or, either has a planned tonsillectomy or underwent a tonsillectomy within 6 months before screening.

    Note: Major surgery typically requires at least 1 night in the hospital.

  16. History of malignancy (including myelodysplastic syndrome) within 5 years of signing the ICF, except for adequately treated non-melanoma skin cancer, superficial bladder cancer, and curatively treated cervical carcinoma-in-situ.

  17. The participant has a history of a severe allergic or anaphylactic reaction to recombinant proteins or excipients used in the mezagitamab or placebo formulation.

  18. The participant has (1) been diagnosed with or has suspected chronic obstructive pulmonary disease (COPD) or asthma and (2) has a prebronchodilatory forced expiratory volume in 1 second (FEV1) <50% of predicted normal at screening.

  19. The participant is capable of breastfeeding but does not agree to forego breastfeeding from first dose of investigational medicinal product (IMP) through 30 days after the last dose of IMP.

  20. The participant is an individual with potential for pregnancy but does not agree to use at least 1 form of highly effective contraception and 1 barrier method of contraception (preferably male condom) when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.

  21. The participant is a sexually active, non-sterilized individual who produces sperm but does not agree to use a barrier method (preferably male condom) combined with at least 1 form of highly effective contraception for any partner(s) with potential for pregnancy when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.

  22. In the investigator's opinion, the participant (and the participant's legally acceptable representative, if applicable per local regulations or determination) is unwilling and/or unable to understand and fully comply with clinical trial procedures and requirements (including digital tools and applications).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Mezagitamab

Participants will receive mezagitamab injections, subcutaneously (SC), for approximately 22 weeks.

Mezagitamab injections administered SC.

Altri nomi:
  • TAK-079
Comparatore placebo: Placebo

Participants will receive mezagitamab-matching placebo injections, SC for approximately 22 weeks.

Mezagitamab-matching placebo injections administered SC.

Sperimentale: Open-label Mezagitamab

Participants will receive mezagitamab injections, SC for approximately 22 weeks.

Mezagitamab injections administered SC.

Altri nomi:
  • TAK-079

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change from Baseline in Proteinuria at Week 36
Lasso di tempo: From Baseline to Week 36

Proteinuria will be assessed by urine protein to creatinine ratio (UPCR) calculated from a 24-hour urine collection.

From Baseline to Week 36

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Variazione rispetto al basale nel tasso di filtrazione glomerulare stimato (EGFR) alla settimana 52 e 104, rispettivamente
Lasso di tempo: Dal basale alle settimane 52 e 104
Dal basale alle settimane 52 e 104
Time From Baseline to the First Occurrence of Sustained Decline in eGFR of ≥30 Percent (%) From Baseline Over at Least 4 Weeks
Lasso di tempo: From Baseline to Week 104
From Baseline to Week 104
Percentage of Participants Who Achieve ≥30% Reduction From Baseline in Proteinuria at Week 104
Lasso di tempo: From Baseline to Week 104
From Baseline to Week 104
The Rate of Change in eGFR From Baseline at Week 104
Lasso di tempo: From Baseline to Week 104

The rate of change in eGFR from baseline is measured as eGFR total slope.

From Baseline to Week 104
Time from Baseline to the First Occurrence of Any of the Pre-specified Kidney Failure Composite Assessment Criteria
Lasso di tempo: From Baseline to Week 104

The pre-specified assessment criteria will include: sustained decline in eGFR of ≥30% from baseline over at least 4 weeks; sustained eGFR <15 mL/min/1.73 m^2 over at least 4 weeks; initiation of maintenance dialysis defined as dialysis performed for at least 4 weeks; receipt of kidney transplant; or death from kidney failure. Time from baseline to first occurrence of any of the above assessment criteria would be reported.

From Baseline to Week 104

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Study Director, Takeda

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 luglio 2025

Completamento primario (Stimato)

7 settembre 2028

Completamento dello studio (Stimato)

14 gennaio 2030

Date di iscrizione allo studio

Primo inviato

30 aprile 2025

Primo inviato che soddisfa i criteri di controllo qualità

30 aprile 2025

Primo Inserito (Effettivo)

9 maggio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

4 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • TAK-079-3001
  • 2025-520825-19-00 (Ctis)
  • 2025 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Criteri di accesso alla condivisione IPD

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi